Ipsen's Sales Growth Could Be Held Back By Generics And Currency In 2021
Dysport Down Due To COVID-19
France’s Ipsen reports a solid financial performance in 2020 but is cautious about guidance for 2021, as the mid-sized pharmaceutical company’s next rare disease candidate nears the market and it looks for early-stage assets to add to its pipeline.
